drugset / Trial / NCT01034410
A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia
RandomizedCrossoverOpen-labelTreatment
Summary
This is an open label randomized controlled phase II study of AS1411 combined with Cytarabine in the treatment of patients with primary refractory or relapsed acute myeloid leukemia.
Timeline
- Start
- 2010-01
- Primary completion
- 2011-01
- Completion
- 2011-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AS1411 | Aptamer | 40 mg/kg | — |
| Subject | AS1411 | Aptamer | 80 mg/kg | — |
| Background | Cytarabine | Small molecule | 2000 mg/m2 | — |